Nanotech Revives Cancer Drug, Offering Hope for Rare Lymphoma

DETROIT, MI – March 25, 2026 – Decades after its initial promise was stymied by biological barriers, a synthetic vitamin A derivative is showing new life as a potential cancer therapy, thanks to modern nanoparticle technology. Detroit-based SciTech Development Inc. announced today that promising early data from its lead drug, ST-001 nanoFenretinide™, will be presented at the prestigious USCLC Annual Workshop in Denver on March 26.

The findings, stemming from a first-in-human Phase 1a trial, demonstrate significant anti-tumor activity and a manageable safety profile in patients with Cutaneous T-Cell Lymphoma (CTCL), a rare and challenging form of non-Hodgkin lymphoma. The results represent a potential breakthrough not only for patients with limited treatment options but also for the drug fenretinide itself, whose potential has long been locked away by its poor absorption in the body.

A New Lifeline for a Difficult Disease

Cutaneous T-Cell Lymphoma is a chronic cancer that primarily manifests in the skin. For patients, the disease can be a debilitating journey marked by persistent and severe itching, painful skin lesions, tumors, and significant impacts on quality of life. While early-stage CTCL can often be managed with skin-directed therapies like topical steroids and light therapy, options become scarce and less effective as the disease progresses or proves resistant to initial treatments.

The current treatment landscape for advanced CTCL involves systemic therapies, including oral retinoids, HDAC inhibitors, and newer monoclonal antibodies. However, these treatments rarely produce a cure, and durable remissions are uncommon. Patients often cycle through therapies as their effectiveness wanes, underscoring a critical unmet need for novel, effective, and well-tolerated treatments that can provide lasting relief and control the disease.

Into this challenging environment comes SciTech's ST-001. The data to be presented by principal investigator Dr. Auris Huen of The University of Texas MD Anderson Cancer Center highlights early clinical findings of "meaningful anti-tumor activity, including complete and partial responses." For a patient population accustomed to incremental gains, the prospect of complete tumor clearance offers a significant glimmer of hope. Furthermore, the announcement of a "favorable safety and tolerability profile" is crucial, as many existing systemic therapies carry a heavy burden of side effects that can diminish a patient's quality of life.

Unlocking a Dormant Cancer Fighter with Nanotechnology

The story of ST-001 is as much about scientific innovation as it is about clinical results. The active agent, fenretinide, is not new. A synthetic retinoid developed in the 1970s, it showed immense promise in preclinical studies for its ability to induce apoptosis, or programmed cell death, in cancer cells. However, its journey to becoming an effective therapy was halted by a fundamental flaw: poor bioavailability.

When taken orally in traditional capsule form, fenretinide is poorly absorbed and rapidly broken down by the liver in a process known as the "first-pass effect." Consequently, achieving therapeutic concentrations of the drug in the bloodstream required massive doses that were impractical and often insufficient. While later attempts with intravenous emulsions showed some activity, they introduced their own toxicities and logistical challenges, requiring lengthy inpatient infusions.

SciTech's breakthrough is its proprietary nanoparticle delivery platform. The company encapsulates fenretinide within a phospholipid matrix, creating tiny particles that fundamentally change how the drug interacts with the body. This technology is designed to protect the drug from premature breakdown and enhance its absorption into the bloodstream. The early trial data provides the first clinical validation of this approach, underscoring the platform's ability to achieve "high systemic exposure." By solving this decades-old bioavailability puzzle, SciTech may have finally unlocked fenretinide's true therapeutic potential.

From Lab to Clinic: The Path Forward

The presentation at the USCLC Annual Workshop, a major gathering of leaders in the field, marks a pivotal moment for the company. The theme of the 2026 workshop, "Frontiers in Cutaneous Lymphoma: New Technologies, Therapeutics, and Future Directions," makes it a fitting venue for unveiling data on such an innovative approach.

The Phase 1a trial is now fully enrolled and nearing completion, with the positive results providing a strong foundation for moving forward. "We are honored to have Dr. Huen present these important findings," said Earle Holsapple, CEO of SciTech Development, in a statement. "Her medical expertise and leadership in CTCL, combined with the encouraging early data, continue to strengthen SciTech's confidence in ST-001 as a potentially impactful therapy for patients with limited treatment options."

This confidence is backed by a clear regulatory path. The data supports advancing ST-001 into the next phase of clinical development, which will likely involve larger patient populations to further confirm efficacy and safety. Each successful clinical stage brings the drug one step closer to potential FDA approval and availability for the patients who need it most.

A Platform for Growth: Beyond Skin-Deep

While the CTCL results are the immediate focus, SciTech is already looking toward a broader horizon for its technology. The company recently announced it had received FDA clearance of its Investigational New Drug (IND) application to begin a clinical trial for ST-001 in Small Cell Lung Cancer (SCLC). This strategic expansion is highly significant, as it suggests the nanoFenretinide platform is not a one-trick pony but a versatile technology applicable to other aggressive cancers.

SCLC is a notoriously difficult-to-treat cancer with poor survival rates, and new therapeutic options are desperately needed. By targeting a completely different malignancy, SciTech is signaling its ambition to leverage its core innovation across multiple oncology indications. This move validates the platform's potential and positions the clinical-stage company for significant growth, transforming it from a firm focused on a rare lymphoma into a potential player in the wider, more competitive oncology market. As the company continues to analyze its data and plan future trials, the medical and investment communities will be watching closely to see if this resurrected drug can fulfill its long-awaited promise.